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core-set were also obtained both at baseline and 4 week apart. These included
tender joint count (out of 28), swollen joint count (out of 28), physician’s and pa-
tient’s global assessment of disease activity, pain score and Westergren erythro-
cyte sedimentation rate (ESR). Disease activity was measured using the DAS28
score, which was obtained at baseline and at the end of the study for each patient.
RESULTS: The median age of the 60 study patients was 48 yr 9.5SD and the
median duration of symptoms was 17months5.5SD. Thirty of these received the
English version of the HAQ and the other 30 received the Hindi version. Baseline
HAQ values for English and Hindi groups were 1.840.48 and 1.910.49, respec-
tively. After treatment, the HAQ values changed to 0.710.42 and 0.620.51, re-
spectively, demonstrating a very good sensitivity to change (Student’s unpaired
t-test: p0.05). Construct validity was assessed using Pearson’s correlation coeffi-
cient between the corresponding values of HAQ and DAS28, both at baseline
(r0.47, p0.05) and after intervention (r0.60, p0.01). CONCLUSIONS: These re-
sults support the validity, and reliability of the IND-HAQas ameasure that captures
the impact of RA on patients’ health-related quality of life.
PMS93
PAPER AND WEB EQUIVALENCE OF THE ENSEMBLE MDS - A TOOL USED TO
COLLECT PHENOTYPIC INFORMATION PRIOR TO TREATMENT
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OBJECTIVES: The ENSEMBLE MDS is a battery of phenotypic generic patient-re-
ported instruments designed for use in clinical studies or comparative effective-
ness research. The component instruments assess baseline patient characteristics
that are believed to be either predictors (health status, illness burden, depression,
anxiety, and perceived stress) or effect-modifying factors (perceived social status,
objective social status, perceived social support, income) of clinical outcomes
and/or treatment response. We sought to evaluate the equivalence of the MDS
across two different modes of administration – paper and web. METHODS: This
study was a data collection effort that used a randomized cross-over design in the
United States (English) and Singapore (Simplified Chinese). Participants were out-
patients with a clinical diagnosis of one of five targeted health conditions: depres-
sion, type 2 diabetes, psoriasis, rheumatoid arthritis and chronic kidney disease.
Those enrolled were randomized to initially complete the MDS on paper or web
format, and returned 24 hours later to complete the alternate format. Equivalence
was evaluated by the intraclass correlation coefficient (ICC) with equivalency de-
fined at or above the minimal acceptable level of 0.70. These analyses were per-
formed individually for each of the nine MDS component measures. RESULTS: A
total of 314 participants (258 in US, 56 in Singapore) were analyzed. In the US,mean
age was 4913 years, 61% were female; in Singapore mean age was 5712, 59%
female. The ICCs between paper and web administration of the different compo-
nents of the ENSEMBLE MDS ranged between 0.74 and 0.98 in the US, and between
0.75 and 0.97 in Singapore. CONCLUSIONS: Equivalence between paper and web-
based administration of the ENSEMBLEMDSwas demonstrated statistically for the
US-English Version and the Chinese version for Singapore, indicating stability of
subject comprehension and response patterns across twomodes of administration
in two different languages and cultures.
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OBJECTIVES: The growth in patient empowerment and increase in on-line patient
pools has given rise to new direct-to-patient research methods (i.e., direct recruit-
ment of patients, without physician sites). One key concern, however, is the ab-
sence of physician-reported data to validate diagnosis and provide other study
data. The objective of this study was to employ a direct-to-patient approach to
collect patient-reported outcomes (PRO) and medical record (MR) information.
METHODS: In July 2011, a random sample of US MediGuard.org members age 18 to
80 were invited to participate via email based on a gout treatment or diagnosis in
their profile. Interestedmembers clicked on an email link to access study informa-
tion and screen based on self-reported diagnosis andwillingness to releasemedical
records. The first 50 consenting participants continued on to complete an online
survey and electronic and paper medical release forms. Completed forms were
provided to Outcomes Health Information Solutions to contact physicians and
obtain participant charts. RESULTS: A total of 120 members clicked on 1250 emails
sent (9.6%). 5 members (4%) explicitly declined to participate due to the medical
record requirement, although this could be as high as 38% if all individuals closing
the browser are included. Of the 50 participants completing the on-line survey and
electronic release, 42 (84%) returned the paper form.With these forms,we obtained
38 of 50 charts (76%): 28 of 38 (74%) with electronic and 10 of 38 (26%) with paper; 35
charts had a gout diagnosis and an additional 2 had a goutmedication; only 1 chart
was missing any mention of gout. CONCLUSIONS: Patients can be recruited di-
rectly for observational study designs that include PRO and MR data with over 75%
data completeness. Although concern exists regarding validity of self-reported di-
agnosis, in this PROMR pilot, nearly all (37 of 38) charts confirmed patient-re-
ported data.
RESPIRATORY-RELATED DISORDERS – Clinical Outcomes Studies
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ASSESSING THE ASSOCIATION OF OMALIZUMAB USE AND
ARTERIOTHROMBOTIC EVENTS THROUGH SPONTANEOUS ADVERSE EVENT
REPORTING
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OBJECTIVES:Omalizumab is amonoclonal antibody, indicated for the treatment of
severe allergic asthma. In Europe, there have been concerns about the cardiovas-
cular safety of omalizumab. The objective of this study is to analyze the association
between omalizumab and arterial thrombotic events (ATE) in spontaneous adverse
drug reaction reporting database in the United States. METHODS: Reports of ATE
submitted to the US Food and Drug Administration’s Adverse Event Reporting
System (AERS) between 2004 and 2011were retrieved and analyzed by the reporting
odds ratio (ROR) data mining algorithm. The ROR of ATE for omalizumab was
compared to specific asthma medications and all drugs in the AERS. Values of 1
are considered significant safety signals. Medical Dictionary for Regulatory Activi-
ties (MedDRA) Preferred Terms were used to retrieve ATE (e.g. stroke, myocardial
infarction). RESULTS: A total of 293,783 reports of ATE were retrieved (about 2% of
all ADR reports), corresponding to 2,274 asthma drug-event pairs (omalizumab,
222; inhaled corticosteroids (ICS), 131; long-acting beta-agonists (LABA), 102; sin-
gle-device combination ICS/LABA, 506; inhaled short-acting beta-agonists (SABA),
475; oral SABA, 6; inhaled antimuscarnics (AMC), 477; single-device combination
AMC/SABA, 127; xanthines, 50; leukotrienemodifiers, 174; andmast cell stabilizers,
4). ROR and 95%CI values for omalizumab compared to other asthma drugs and all
drugs in AERS were 2.75 (2.39-316) and 1.09 (0.95-1.24), respectively. Omalizumab
ranked the second after ICS in the risk of ATE; followed by AMC, AMC/SABA, and
ICS/LABA. CONCLUSIONS: Omalizumab is associated with higher than expected
reporting of arterial thrombotic events in asthmatic patients. This hypothesis
needs further testing in robust epidemiologic studies.
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OBJECTIVES: To evaluate the incidence of various side effects in newly diagnosed
tuberculosis patients of Khyber Pakhtoon Khuwa. METHODS: Quantitative study
was conducted to evaluate the incidence of side effects in tuberculosis patients.
Data was collected fromMedicine, Infectious diseases, and chest and gastroenter-
ology unit of the Ayub Teaching Hospital and T.B center at DHQ Hospital of KPK. A
total of 125 random newly diagnosed patients were included in the studies which
were given 1st line ATT which include Rifampicin, Pyrazinamide, Isoniazid and
Ethambutol. This 4 drug regimen was given to initiate the therapy. A formal con-
sent was taken from the patient or the attendant. The patients were examined for
signs of previous liver or kidney disease by physical examination. Liver function
tests and urine RE, as well as blood CP and hematological investigations. RESULTS:
Patients were given 4 drug regime i.e., isoniazid (INH),rifampicin, pyrazinamide
and ethambutol. A total of 31.97% patients experienced nausea; 25.4% patients
experienced anorexia; 13% patients experienced vomiting; and 11.4% patients ex-
perienced diarrhea. Hypersensitivity reaction were also noticed, 12.3 % people suf-
fered from fever. Skin rashes were experienced by 16 (13.11%) patients. Hepatotox-
icity was seen in 9.01% patients; (0.82%) patients suffered from thrombocytopenia
whowas a female; 1.64% patients experienced renal failure; 1(50%) was amale and
1(50%)was a female; and 99.18% patients experienced urinary discolouration out of
which 81 (66.94%) were males and 34 (28.1%) were females. Two patients (1.64%)
experienced acne, bothweremales.CONCLUSIONS:Various adverse effects of Anti
Tuberclosis Therapy have been observed in the patients ranging from the minor
symptoms like skin rashes and GI disturbances to serious effects like renal failure,
hepatotoxicity, thrombocytopenia, hyperuricemia which may be fatal. There is a
need of optimal patient care during the period of therapy. Many of these side
effects can be avoided by altering the regimen and proper counseling.
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INHALED ANTICHOLINERGICS AND RISK OF ALL-CAUSE MORTALITY IN
PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A
SYSTEMATIC REVIEW AND META ANALYSIS OF RANDOMIZED CONTROLLED
TRIALS
Ajmera MR, Rane PB, Kelley G, Sambamoorthi U
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Inhaled anticholinergics are important pharmacologic interventions
in the management of Chronic Obstructive Pulmonary Disease (COPD) with tiotro-
pium bromide being themost prescribed COPDmedication. Concerns regarding its
association with cardiovascular adverse events have been raised. The objective of
this study was to assess the risk of all-cause mortality associated with inhaled
anticholinergics among COPD patients using systematic-review with meta-analy-
sis techniques.METHODS: A systematic literature search was conducted using six
electronic databases (PubMed, Scopus, Web-of-Science, Web-of Knowledge, Co-
chrane Central Register of Controlled Trials and Proquest) and cross-referencing.
Studies meeting the following eligibility criteria were selected: 1) randomized con-
trolled trials (RCTs) withmortality data; 2) adults aged greater35 yearswith COPD
of any severity; 3) inhaled anticholinergics (ipratropium bromide or tiotropium
bromide) with a minimum follow-up of 4 weeks; and 4) placebo or active control
group. Studies including asthma patients were excluded. Data extraction was per-
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formed independently and relative risk (RR) estimates were calculated from each
study. To determine the relationship between inhaled anticholinergics and mor-
tality, datawere pooled using the randomeffectsmodel (inverse variancemethod).
Between-study heterogeneity was assessed using the I2-statistic. RESULTS: Of the
684 citations reviewed, a total of 18 RCTs enrolling more than 33,000 patients met
the inclusion criteria. Inhaled anticholinergics were not associated with an in-
creased risk of all-causemortality [RR1.10 (95%CI: 0.88,1.36), I236%]. Tiotropium
only group showed similar results. Subgroup analyses of soft mist inhaler (SMI)
trials, however, revealed a 51% increase in all-cause mortality for the intervention
group [RR1.51; 95% CI (1.08,2.11), I20%]. Sensitivity analysis did not change any
of the results. CONCLUSIONS: Overall, inhaled anticholinergics were not associ-
ated with an increased risk of all-cause mortality and might be considered as safe.
Analyses of tiotropium-SMI subgroup, however, suggested an increase inmortality
risk, necessitating more long term RCTs to assess its safety.
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OBJECTIVES: To assess the comorbid relationship between COPD and depression/
anxiety among Medicare beneficiaries. METHODS: Fee-for-service (FFS) part A, B
and D claims from the 5% Medicare Chronic Conditions Warehouse (CCW) from
January 1, 2006 to December 31, 2007were pooled to construct a prevalent cohort of
patients aged 65 with COPD (ICD-9-CM 491, 492, or 496). Depression/anxiety was
measured via health care services or prescription drug claims. Baseline character-
istics were assessed from January 1, 2006 to June 30, 2006 and patients were fol-
lowed from first depression/anxiety claim until December 31, 2007 for all-cause
and respiratory-related healthcare cost and utilization. COPD exacerbations were
defined as either moderate [outpatient encounter with an oral corticosteroid
and/or an antibiotic claim, or COPD-related emergency department visit] or severe
(COPD-related hospital admission). Prevalence estimates of co-occurring COPDand
depression/anxiety were estimated. Generalized linear models with a gamma dis-
tribution and a log link were used to model total and respiratory-related annual
adjusted costs. Risk of amoderate, severe, or any exacerbationwas estimated using
logistic regressionmodels.RESULTS:Of the 1,591,413 enrolleesmeeting the criteria
of 12 months of FFS coverage, 137,275 were selected from the 5% CCW sample.
Depression/anxiety was found in 55% (75,375) of the cohort. After controlling for
sex, age, region, race, Charlson comorbidity score, and use of COPD-related medi-
cations in the baseline period, enrolleeswith depression/ anxiety had a 51% greater
risk of having a moderate exacerbation (OR 1.51, 95% CI 1.39-1.64) and 78% higher
risk of a severe exacerbation (OR 1.78, 95% CI 1.50-2.11). After adjustment, depres-
sion/anxiety was associated with $50,622 (95% CI 49,007-52,237) greater annual
total cost and $35,789 annual respiratory-related costs (95% CI 34,328-37,251).
CONCLUSIONS: Clinical and economic costs associated with depression/anxiety
among COPD Medicare FFS enrollees are substantial. More emphasis should be
placed on identification and treatment of depression/anxiety among this popula-
tion.
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OBJECTIVES: Depression is a common co-morbid condition in patients with
asthma and is associatedwithworsening of asthmaoutcomes. Increased symptom
burden increases health care utilization and may lead to increased health care
expenditures. The purpose of this study was to assess whether individuals with
asthma and co-morbid depressive disorders have higher health care expenditures
compared to individuals with asthma alone. METHODS: Two cohorts of patients
with or without co-morbid depression were formed from the 2009 Medical Expen-
diture Panel Survey (MEPS). Propensity score (PS) matching technique was used to
balance the cohorts on various parameters such as demographic information, in-
surance status. Patients with co-morbid depression were matched to patients
without co-morbid depression on the logit of propensity score using calipers of
width equal to 0.2 of the standard deviation of the logit of the propensity score.
Difference in the health care expenditure of patients with co-morbid depression
and those with asthma alone was calculated using the independent sample t test.
RESULTS: Of the total 29,282 survey respondents, 8.1% (n2,375) were asthmatic.
The prevalence of co-morbid depression in asthma patients (12.33%, n293) was
comparatively higher than the prevalence of depression (7.55%, n2,212) in the rest
of the survey population. The total average health care expenditure of asthmatic
patients with co-morbid depression ($15,427.33 ) was significantly higher than the
health care expenditure of matched asthma patients without depression
($10,243.80) (p 0.02). CONCLUSIONS: Asthmatic individuals with co-morbid de-
pression have higher health care expenditures compared to individuals with
asthma alone, even after adjusting for differences in demographic information and
insurance status. Further research is required to investigate the causal relationship
between increase in health care expenditure of asthmatic patients with co-morbid
depression.
PRS6
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OBJECTIVES: This study evaluated the impact of omalizumab on emergency-de-
partment (ED) visits, hospitalizations and corticosteroid use among uncontrolled
asthma patients using high-dose inhaled corticosteroids (ICS) prior to initiating
omalizumab. METHODS: Health insurance claims from the MarketScan database
(2002Q1-2009Q1) were analyzed. Patients with 12 months of continuous insur-
ance coverage prior to and after the first omalizumab dispensing, 8 weeks of
high-dose ICS use, 8 weeks of long-acting beta2-agonist (LABA) use, and uncon-
trolled asthma at baseline were included. A retrospective analysis was conducted
to quantify the impact of omalizumab on resource use by comparing ED visits,
hospitalizations, and corticosteroid use one year before and after omalizumab
initiation. A one-year period was chosen to cover any potential seasonality
impacts. RESULTS: A total of 644 patients (mean age: 49.9; female: 59.2%) formed
the study population. Omalizumab was associated with a 48.6% reduction in the
proportion of patients with 1 asthma-related ED visits (pre vs. post-omalizumab
period: 21.4% vs. 11.0%, P0.001) and 40.8% reduction in asthma-related hospital-
izations (25.0% vs. 14.8%, respectively, P0.001). Compared to the pre-omalizumab
period, the use of ICS decreased significantly after omalizumab initiation (7.8 vs. 6.5
dispensings, P0.001; 41.9% of patients had a reduction in ICS use). A similar re-
duction in oral corticosteroid use was observed (5.0 vs. 3.6 dispensings, P.001;
53.3% of patients had a reduction in oral corticosteroid use). CONCLUSIONS: The
results of the current study showed that omalizumab treatment initiation was
associatedwith statistically significant reductions in EDvisits, hospitalizations and
corticosteroid use.
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OBJECTIVES: Utility based health outcome measures add more meaning to eco-
nomic outcome analysis involving health related quality of life (HRQoL) assess-
ments. The purpose of this study was to compare the cost effectiveness and utility
analysis of inhaled corticosteroids like fluticasone, beclomethasone and budes-
onide at equipotent doses in asthma patients with patients’ perspective.
METHODS: A prospective study was conducted on 187 asthmatics of GINA (Global
Initiative on Asthma) grade-II, III and IV severity who received equipotent doses of
either beclomethasone dipropionate (BDP), budesonide (BUD) or fluticasone (FP) for
six months duration. As the cost analysis focused on patients’ perspective, the
meanmonthly cost on the Inhaled Corticosteroid (ICS) treatments were calculated
based on both direct and indirect cost incurred. The percentage satisfaction was
recorded on a 10cm Visual Analogue Scale (VAS) and QoL assessment performed
using Saint Georges Respiratory Questionnaire (SGRQ). Treatment efficacy was
compared using improvement in FEV1 (Forced Expiratory Volume in 1 second).
Statistical analysis was performed using SPSS version-13.0. RESULTS: The overall
QoL interpretation by VAS and SGRQ-total scores were checked for its association
and found to be significantly correlating (r -0.79, p0.01). Themean cost per unit
satisfaction (cost utility value) considering QoL improvement and the average cost
effective ratio (ACER) were assessed for ICS treatments. Cost per unit satisfaction
with ICS was comparable (p0.05) between treatments, where BUD group showed
value in Indian Rupees 7.92/-, FP-7.81/- and BDP-7.66/-. ACER with individual ther-
apy also showed similar results between the ICS groups (BUD-0.93, FP-0.95, and
BDP-1.06). CONCLUSIONS: The study observed no significant difference between
ICS groups with respect to cost utility value. At equipotent doses fluticasone, how-
ever, is similar to that of budesonide but more cost effective than beclomethasone
dipropionate.
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EVALUATION OF THE ASSOCIATION BETWEEN STATIN USE AND RISK OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION
Wang MT, Lo YW
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OBJECTIVES: To examine whether use of statins reduces the risk of hospitalization
for a chronic obstructive pulmonary disease (COPD) exacerbation. METHODS: A
nested case-control study of all patients diagnosed with COPD (ICD-9-CM codes
491-492, 496) and receiving COPDmedications were conducted between January 1,
2000 andDecember 31, 2008, using the TaiwanNational Health Insurance Research
Databases. Cases were defined as those admitted for COPD exacerbations. Each
case was matched to four randomly-selected controls by age, sex and cohort entry
date. Any use of statins was evaluated during the follow-up period and further
categorized by recency, average daily dose and duration of statin use. Conditional
logistic regressions were employed to estimate odds ratios (ORs). RESULTS: The
study cohort comprised 14,316 COPD patients, from which 1620 cases with COPD
exacerbations and 6432 matched controls were identified. Any use of statins was
associated with a 33% decreased risk of hospitalization for COPD exacerbation
(adjusted OR, 0.67; 95% CI, 0.54-0.83). A significant reduction in the risk for COPD
exacerbation was only observed among current users of statins (180 days; ad-
justed OR, 0.60; 95% CI, 0.45-0.81). Statins prescribed at an average daily dose of
0.45-0.60 defineddaily dose (DDD, adjustedOR, 0.52; 95%CI, 0.34-0.80) or0.60DDD
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